Spots Global Cancer Trial Database for abiraterone
Every month we try and update this database with for abiraterone cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients | NCT03569280 | Castration-Resi... | Enzalutamide or... | 18 Years - | Kangpu Biopharmaceuticals, Ltd. | |
| Abiraterone Acetate for Castrate Resistant Prostate Cancer | NCT01961843 | Prostate Cancer | Abiraterone Prednisone | 18 Years - | Massachusetts General Hospital | |
| Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT05520138 | Prostatic Neopl... | Enzalutamide Abiraterone ace... | 18 Years - | Pfizer | |
| A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer | NCT01685983 | Prostate Cancer | Abiraterone ace... Prednisolone | 18 Years - | Janssen Research & Development, LLC | |
| Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer | NCT01995058 | Prostate Cancer Castration Resi... Prostatic Neopl... | cabozantinib abiraterone prednisone | 18 Years - | Exelixis | |
| A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer | NCT01424930 | Prostate Neopla... Prostate Cancer | Abiraterone Prednisone | 18 Years - | Janssen-Ortho Inc., Canada | |
| Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer | NCT02254785 | Metastatic Cast... | cabazitaxel Abiraterone Enzalutamide 16... | 18 Years - | British Columbia Cancer Agency | |
| Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | NCT04262154 | Metastatic Pros... | Atezolizumab Abiraterone Prednisone GnRH analog Stereotactic Bo... Enzalutamide Follow up | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate | NCT03356444 | Prostate Cancer Castration-resi... Drug | Abiraterone Ace... Docetaxel | 40 Years - | West China Hospital | |
| Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer | NCT01995058 | Prostate Cancer Castration Resi... Prostatic Neopl... | cabozantinib abiraterone prednisone | 18 Years - | Exelixis | |
| Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer | NCT05733351 | Castration-Sens... Metastatic Pros... Stage IVB Prost... | Abiraterone Biospecimen Col... Bone Scan Computed Tomogr... Docetaxel Enzalutamide FDG-Positron Em... Magnetic Resona... PSMA PET Scan Vudalimab | 18 Years - | Emory University | |
| Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | NCT01485861 | Prostate Cancer | Abiraterone Apitolisib Ipatasertib Placebo Prednisone Prednisolone | 18 Years - | Genentech, Inc. | |
| Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer | NCT06134271 | Metastatic Horm... | Rezvilutamide Rezvilutamide p... Continue previo... | 18 Years - | First Hospital of China Medical University | |
| Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery | NCT01780220 | Biochemically-r... | Abiraterone | 18 Years - | UNICANCER | |
| A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer | NCT05376722 | Neoadjuvant The... | pamiparib abiraterone prednisone | 18 Years - 80 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment | NCT04647526 | Metastatic Cast... | [Lu-177]-PNT200... Abiraterone Enzalutamide | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer | NCT03565835 | Prostatic Neopl... | Abiraterone Ace... Prednisone | 18 Years - | Montefiore Medical Center | |
| Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels | NCT02867020 | Prostate Cancer | Apalutamide Abiraterone ADT Prednisone | 18 Years - | Latin American Cooperative Oncology Group | |
| A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC | NCT04108247 | Prostate Cancer... | Abiraterone+SHR... | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone | NCT03934840 | Prostate Cancer | Cabazitaxel Carboplatin Abiraterone Prednisone | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | NCT06430411 | Prostate Cancer... Prostate Cancer... Prostate Cancer Prostate Neopla... Oligometastatic... Oligometastasis | Radical prostat... Prostate irradi... Surgical metast... Irradiation of ... Abiraterone ace... Enzalutamide Darolutamide Apalutamide Docetaxel Lutetium-PSMA Androgen depriv... | 18 Years - 80 Years | Medical University of Vienna | |
| A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer | NCT04087174 | Prostate Cancer | Capivasertib Enzalutamide Abiraterone | 18 Years - 130 Years | AstraZeneca | |
| Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | NCT05701007 | Metastatic Cast... Metastatic Cast... | abiraterone enzalutamide docetaxel apalutamide cabazitaxel Radium-223 Lutetium-177 degarelix goserelin leuprorelin triptorelin | 18 Years - | Pfizer | |
| Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases | NCT02758132 | Prostate Cancer | Denosumab Enzalutamide Abiraterone Prednisone | 18 Years - | University of Hawaii | |
| Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study | NCT04175431 | Prostate Adenoc... | Positron Emissi... Lymphadenectomy Radiation Thera... Abiraterone Ace... Prednisone Computed Tomogr... Abiraterone PSMA PET Scan | 18 Years - | University of Washington | |
| Improving Bio-availability of the Expensive Oral Oncolytic Drug Abiraterone by Food Intake | NCT02883166 | Prostate Cancer | abiraterone | 18 Years - | Radboud University Medical Center | |
| A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | NCT06072196 | Prostatic Neopl... | Novel hormonal ... | 65 Years - | Pfizer | |
| Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | NCT04666129 | Metastatic Cast... Metastatic Cast... Non-Metastatic ... | Relugolix Abiraterone Prednisone Methylprednisol... Apalutamide Docetaxel | 18 Years - | Sumitomo Pharma Switzerland GmbH | |
| Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer | NCT02789878 | Prostate Cancer | Goserelin Prednisone Abiraterone Apalutamide | 18 Years - 80 Years | Instituto do Cancer do Estado de São Paulo | |
| Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage | NCT05627752 | Prostate Cancer Castrate Resist... | Enzalutamide 40... Docetaxel injec... | 18 Years - 75 Years | Zhongnan Hospital | |
| Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | NCT04221542 | Prostate Cancer | AMG 509 Abiraterone Enzalutamide | 18 Years - | Amgen | |
| XL-184+Abiraterone in Post-Chemo CRPC | NCT01574937 | Prostate Cancer | Cabozantinib Abiraterone | 18 Years - | Dana-Farber Cancer Institute | |
| Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | NCT03511196 | Prostate Cancer Stage IV Prosta... Advanced Prosta... Adenocarcinoma ... | Adaptive Androg... Abiraterone Prednisone | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients | NCT03569280 | Castration-Resi... | Enzalutamide or... | 18 Years - | Kangpu Biopharmaceuticals, Ltd. | |
| CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone | NCT03934840 | Prostate Cancer | Cabazitaxel Carboplatin Abiraterone Prednisone | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | NCT06430411 | Prostate Cancer... Prostate Cancer... Prostate Cancer Prostate Neopla... Oligometastatic... Oligometastasis | Radical prostat... Prostate irradi... Surgical metast... Irradiation of ... Abiraterone ace... Enzalutamide Darolutamide Apalutamide Docetaxel Lutetium-PSMA Androgen depriv... | 18 Years - 80 Years | Medical University of Vienna | |
| A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer | NCT01685983 | Prostate Cancer | Abiraterone ace... Prednisolone | 18 Years - | Janssen Research & Development, LLC | |
| Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer | NCT03298087 | Newly Diagnosed... | radical prostat... stereotactic bo... Leuprolide apalutamide abiraterone | 18 Years - | VA Office of Research and Development | |
| XL-184+Abiraterone in Post-Chemo CRPC | NCT01574937 | Prostate Cancer | Cabozantinib Abiraterone | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer | NCT02116582 | Metastatic Cast... | Enzalutamide | 18 Years - | Astellas Pharma Inc | |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects | NCT06014853 | Prostate Cancer | SOL-804-F Zytiga | 19 Years - 50 Years | Bukwang Pharmaceutical | |
| A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel | NCT01795703 | Prostate Cancer | Abiraterone Prednisolone | 20 Years - | Janssen Research & Development, LLC | |
| RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) | NCT02090114 | Prostate Cancer | Testosterone cy... Testosterone En... Abiraterone ace... Enzalutamide | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | NCT04726332 | Neoplasm Malign... Epithelial Ovar... Triple Negative... Hormone Recepto... Metastatic Cast... | XL102 Fulvestrant Abiraterone Prednisone | 18 Years - | Exelixis | |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SOL-804 in Healthy Male Subjects | NCT06014853 | Prostate Cancer | SOL-804-F Zytiga | 19 Years - 50 Years | Bukwang Pharmaceutical | |
| A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer | NCT04087174 | Prostate Cancer | Capivasertib Enzalutamide Abiraterone | 18 Years - 130 Years | AstraZeneca | |
| Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP) | NCT05705700 | Prostate Cancer | Dutasteride Abiraterone | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | NCT00268476 | Prostate Cancer | Celecoxib Docetaxel Prednisolone ADT Zoledronic Acid Abiraterone Radiotherapy to... Enzalutamide Metformin Transdermal Oes... | - 120 Years | Medical Research Council | |
| Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial | NCT05188911 | Prostate Cancer Castration-resi... Metastatic Dise... | Abiraterone Prednisone Androgen depriv... | 18 Years - 85 Years | Fudan University | |
| Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone | NCT02380313 | Cancer | Afuresertib Enzalutamide Abiraterone Prednisone | 18 Years - | GlaxoSmithKline | |
| Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509) | NCT03141671 | Prostate Cancer | GnRH Bicalutamide Salvage radiati... Abiraterone Prednisone Apalutamide | 18 Years - 95 Years | Dana-Farber Cancer Institute | |
| AASUR in High Risk Prostate Cancer | NCT02772588 | Prostate Cancer | ARN-509 Abiraterone Leuprolide stereotactic, u... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | NCT04666129 | Metastatic Cast... Metastatic Cast... Non-Metastatic ... | Relugolix Abiraterone Prednisone Methylprednisol... Apalutamide Docetaxel | 18 Years - | Sumitomo Pharma Switzerland GmbH | |
| A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel | NCT01795703 | Prostate Cancer | Abiraterone Prednisolone | 20 Years - | Janssen Research & Development, LLC | |
| Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer | NCT01828476 | Prostate Cancer | Abiraterone ABT-263 Hydroxychloroqu... | 18 Years - | Rutgers, The State University of New Jersey | |
| Sequencing Abiraterone and Enzalutamide in mCRPC | NCT02125357 | Metastatic Cast... | Abiraterone ace... Enzalutamide | 18 Years - | British Columbia Cancer Agency | |
| A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer | NCT05968599 | Prostatic Neopl... | Enzalutamide Abiraterone ace... | 18 Years - | Pfizer | |
| Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer | NCT04262154 | Metastatic Pros... | Atezolizumab Abiraterone Prednisone GnRH analog Stereotactic Bo... Enzalutamide Follow up | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer | NCT03150056 | Solid Tumours | GSK525762 Abiraterone Enzalutamide Prednisone | 18 Years - | GlaxoSmithKline | |
| Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | NCT01949337 | Adenocarcinoma ... Hormone-resista... Recurrent Prost... Stage IV Prosta... | enzalutamide abiraterone prednisone | 18 Years - | Alliance for Clinical Trials in Oncology | |
| AMG 386 and Abiraterone for Advanced Prostate Cancer | NCT01553188 | Prostatic Neopl... Prostate Cancer Neoplasm, Prost... Neoplasm,Prosta... | AMG 386 Abiraterone Prednisone | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel | NCT03295565 | Prostate Cancer... Metastasis | Cabazitaxel Abiraterone Enzalutamide | 18 Years - | The Netherlands Cancer Institute | |
| Micro RNAs to Predict Response to Androgen Deprivation Therapy | NCT02366494 | Prostate Cancer | Bicalutamide Leuprolide Goserelin Triptorelin Docetaxel Abiraterone Apalutamide Enzalutamide | 21 Years - 85 Years | Medical College of Wisconsin | |
| BKM120+Abiraterone Acetate for Metastatic CRPC | NCT01741753 | Prostate Cancer | BKM120 Abiraterone Prednisone | 18 Years - | Dana-Farber Cancer Institute | |
| Abiraterone Acetate for Castrate Resistant Prostate Cancer | NCT01961843 | Prostate Cancer | Abiraterone Prednisone | 18 Years - | Massachusetts General Hospital | |
| Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) | NCT05520138 | Prostatic Neopl... | Enzalutamide Abiraterone ace... | 18 Years - | Pfizer | |
| A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer | NCT05376722 | Neoadjuvant The... | pamiparib abiraterone prednisone | 18 Years - 80 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone | NCT03934840 | Prostate Cancer | Cabazitaxel Carboplatin Abiraterone Prednisone | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial | NCT06378866 | Recurrent Castr... Stage IVB Prost... Recurrent Prost... Castration-resi... | Abiraterone Apalutamide Biospecimen Col... Bone Scan Computed Tomogr... Darolutamide Degarelix Enzalutamide Goserelin Histrelin Leuprolide Magnetic Resona... Patient Observa... Positron Emissi... Prednisone Questionnaire A... Relugolix Stereotactic Bo... Triptorelin | 18 Years - | Mayo Clinic | |
| Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | NCT06173362 | Advanced Prosta... Stage III Prost... Stage IV Prosta... | Abiraterone Biospecimen Col... Darolutamide Prednisone | 18 Years - | University of California, Davis | |
| Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer | NCT05361915 | Prostate Cancer Prostate Cancer... | Abivertinib Abiraterone | 18 Years - | Sorrento Therapeutics, Inc. | |
| Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients | NCT03173859 | Prostatic Neopl... | Abiraterone Apalutamide | 18 Years - | University of Athens | |
| Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). | NCT03896984 | Metastatic Cast... | Radium-223 (Xof... Abiraterone Enzalutamide | - | Bayer | |
| Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer | NCT03565835 | Prostatic Neopl... | Abiraterone Ace... Prednisone | 18 Years - | Montefiore Medical Center | |
| Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer | NCT03860987 | Castrate Sensit... | goserelin Enzalutamide Abiraterone 18F-DCFPyL Prednisone Radical Prostat... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | NCT03678025 | Castration Leve... Metastatic Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Bicalutamide Degarelix Docetaxel Flutamide Goserelin Aceta... Histrelin Aceta... Leuprolide Acet... Nilutamide Orchiectomy Prednisone Quality-of-Life... Radiation Thera... Radical Prostat... Triptorelin | 18 Years - | SWOG Cancer Research Network | |
| Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) | NCT04748042 | Prostate Cancer Castrate Sensit... Oligometastatic... | Abiraterone Prednisone External Beam R... Androgen Depriv... Olaparib | 18 Years - | University of Michigan Rogel Cancer Center | |
| Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer | NCT03565835 | Prostatic Neopl... | Abiraterone Ace... Prednisone | 18 Years - | Montefiore Medical Center | |
| Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients | NCT01995513 | Prostate Cancer | Enzalutamide Abiraterone Placebo for Enz... Prednisone | 18 Years - | Pfizer | |
| Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer. | NCT01972217 | Metastatic Cast... | Olaparib Placebo Abiraterone Prednisone or p... | 18 Years - 130 Years | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
